3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
35
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Surveys and Questionnaires
53
Blood Specimen Collection
53
Specimen Handling
28
Radiotherapy
18
Observation
18
Interviews as Topic
13
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
10
Drug Therapy
10
Data Collection
10
Biopsy
10
Tomography, X-Ray Computed
9
darolutamide
8
Watchful Waiting
7
Standard of Care
7
ribociclib
6
palbociclib
6
Restraint, Physical
6
Patient Reported Outcome Measures
6
Magnetic Resonance Imaging
6
Immune Checkpoint Inhibitors
6
trastuzumab deruxtecan
5
Positron-Emission Tomography
5
Mass Screening
5
Genetic Testing
5
Esophagectomy
5
Breath Tests
5
Bevacizumab
5
enzalutamide
4
apalutamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
avelumab
×
90 days
×
Clear all
NCT04822350
2026-04-02
AVENANCE
Pfizer
Completed
596 enrolled
43 charts